Drugs / Nezastomig
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06826768 | Jul 2025 → May 2027 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07850921 | Jun 2027 → Jul 2031 expected | prostate carcinoma | Regeneron Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06085664 | Dec 2023 → Jun 2028 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05125016 | Nov 2021 → Mar 2030 expected | castration-resistant prostate carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03972657 | Aug 2019 → Nov 2027 expected | castration-resistant prostate carcinoma, clear cell renal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-08-03 | Regeneron Pharmaceuticals | Results Regeneron Reports Second Quarter 2023 Financial and Operating Results regeneron.com ↗
As a result, the Company has discontinued enrollment of patients receiving the combination of REGN5678 and full-dose Libtayo, and plans to explore REGN5678 combinations with lower doses of Libtayo. |
| 2022-08-03 | Regeneron Pharmaceuticals | Results Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) regeneron.com ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2 trial investigating REGN5678, a novel PSMAxCD28 costimulatory bispecific antibody, in combination with the company's PD-1 inhibitor Libtayo® (cemiplimab) in advanced metastatic castration-resistant prostate cancer (mCRPC). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-03 | Regeneron Pharmaceuticals | Regeneron Reports Second Quarter 2023 Financial and Operating Results regeneron.com ↗ |
| 2022-08-03 | Regeneron Pharmaceuticals | Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) regeneron.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nezastomig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07850921 ↗ |
| Known as | REGN5678 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05125016 ↗ |
| Modality | Monoclonal antibody | “REGN5678 (a PSMAxCD28 Bispecific Antibody)” NCT05125016 ↗ |
| Route | Intravenous | “Given by IV (vein)” NCT06085664 ↗ |